TCL currently represents a class of end payors (for example, insurers) in a recently settled antitrust suit against the makers of Tracleer, a blockbuster heart medication. In that case—Government Employees Health Association v. Actelion Pharmaceuticals Ltd., 18- cv-3560 (D. Md.)—the plaintiffs alleged that the defendants refused to provide Tracleer samples to generic-drug manufacturers. This in turn prevented the manufacturers from developing generic Tracleer, which allowed the defendants to extend their monopoly over the heart medication, and to continue selling Tracleer at inflated prices. On the eve of trial, this case settled for $65 million, and on March 13, 2026, the settlement received preliminary approval. A final-approval hearing is currently scheduled for July 1, 2026.